M. Kobayashi

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Gastroenterology.

Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Virology Journal.

A Pilot Study of Thymosin α1 Therapy for Chronic Hepatitis B Patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003 .

A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Internal medicine.

Precore Wild-Type Hepatitis B Virus with G1896 in the Resolution of Persistent Hepatitis B Virus Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Low serum level of hepatitis B core‐related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy

M. Imamura, K. Chayama, T. Okanoue, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Efficacy of switching to entecavir monotherapy in Japanese lamivudine‐pretreated patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of gastroenterology and hepatology.

Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2010, Hepatology.

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP‐424), pegylated interferon and ribavirin for 12 weeks

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology.

Diagnostic Problems Caused by HBsAg Mutants – A Consensus Report of an Expert Meeting

P. Coursaget, Yoshiyuki Suzuki, O. Yokosuka, 2004, Intervirology.

Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Intervirology.

Effect of Acute Self-Limited Hepatitis C Virus (HCV) Superinfection on Hepatitis B Virus (HBV)-Related Cirrhosis. Virological Features of HBV–HCV Dual Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Digestive Diseases and Sciences.

Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology communications.

Impact of hepatitis B core‐related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Alimentary pharmacology & therapeutics.

HBcrAg is a predictor of post‐treatment recurrence of hepatocellular carcinoma during antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C

K. Chayama, K. Ikeda, H. Kumada, 1991, Hepatology.

Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay.

K. Tadokoro, Toshikazu Yamaguchi, M. Nagano, 2011, Journal of virological methods.

Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Journal of Gastroenterology.

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of Gastroenterology.

Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Journal of gastroenterology and hepatology.

Increase of rtA181T mutant strains during entecavir therapy for a patient with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010 .

Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of Gastroenterology.

Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes.

K. Tadokoro, Toshikazu Yamaguchi, Toru Egashira, 2006, Journal of virological methods.

Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of Gastroenterology.

Randomized, controlled trial of natural interferon-α therapy for e-antigen-positive chronic hepatitis B patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002 .

Randomized, controlled trial of natural interferon-alpha therapy for e-antigen-positive chronic hepatitis B patients.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B

K. Chayama, Y. Karino, N. Hiramatsu, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Long-Term Presence of HBV in the Sera of Chronic Hepatitis B Patients with HBsAg Seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Intervirology.

Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, The American journal of medicine.

Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of medical virology.

Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of Gastroenterology.

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis.

M. Buti, A. Lok, Y. Chong, 2019, Gastroenterology.

Clinical features of hepatitis B virus genotype A in Japanese patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of medical virology.

Progressive and sufficient decrease of hepatitis B core antibody can predict the disappearance of hepatitis B virus DNA in Japanese patients with hepatitis B surface antigen clearance

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Factors predictive of response to interferon‐α therapy in hepatitis C virus infection

K. Chayama, A. Tsubota, K. Ikeda, 1994, Hepatology.

Hepatitis G virus infection after blood transfusion in patients with chronic liver disease treated surgically for hepatocellular carcinoma

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1997 .

Time course of histological changes in patients with a sustained biochemical and virological response to corticosteroid withdrawal therapy for chronic hepatitis B

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, American Journal of Gastroenterology.

Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Extending Combination Therapy with Peginterferon plus Ribavirin for Genotype 2 Chronic Hepatitis C Virological Responders: A Pilot Study of 7 Cases

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Intervirology.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Internal medicine.

Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Internal medicine.

Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Intervirology.

Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2004, Journal of Gastroenterology.

Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Prevalence of TT virus before and after blood transfusion in patients with chronic liver disease treated surgically for hepatocellular carcinoma

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Journal of gastroenterology and hepatology.

Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Change of hepatitis B virus genotypes in acute and chronic infections in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare‐up

N. Hiraga, Yoshiyuki Suzuki, M. Kobayashi, 2005, Journal of medical virology.

Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon‐alpha‐2b and ribavirin in hepatitis C patients

Yoshiyuki Suzuki, H. Tsuda, M. Kobayashi, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Predictive factors of virological non‐response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of hepatology.

Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Scandinavian journal of gastroenterology.

Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study

T. Hibi, Yasuo Suzuki, Mariko Kobayashi, 2020, Intestinal research.

Predictive factors in eradicating hepatitis C virus using a relatively small dose of interferon

K. Chayama, A. Tsubota, M. Kobayashi, 1998, Journal of gastroenterology and hepatology.

Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Hepatology International.

An encapsulated bulky abdominal abscess due to amoeba

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Clinical Journal of Gastroenterology.

Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus

K. Chayama, Yoshiyuki Suzuki, M. Kobayashi, 2012, Journal of Gastroenterology.

Usefulness of HCV-RNA counts by the method of HCV-bDNA probe in interferon retreatment for patients with HCV-RNA positive chronic hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1995 .

Genotypic subtyping of hepatitis C virus

K. Chayama, A. Tsubota, K. Ikeda, 1993, Journal of gastroenterology and hepatology.

Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 2a High Viral Load and Virological Response to Interferon-Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: Multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Scandinavian journal of gastroenterology.

Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN‐resistant cases with hepatocyte steatosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of medical virology.

Quantitative analysis of hepatitis C virus RNA by competitive nested polymerase chain reaction

K. Chayama, A. Tsubota, K. Ikeda, 1993 .

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

Yusuke Nakamura, M. Imamura, K. Chayama, 2010, Gut.

Factors useful in predicting the response to interferon therapy in chronic hepatitis C

K. Chayama, A. Tsubota, K. Ikeda, 1993, Journal of gastroenterology and hepatology.

Antiviral effect of lymphoblastoid interferon‐alpha on hepatitis C virus in patients with chronic hepatitis type C

K. Chayama, A. Tsubota, K. Ikeda, 1994, Journal of gastroenterology and hepatology.

Relationship between pretreatment viremia level and response to interferon-α therapy in chronic hepatitis c differs in viral type 1 and 2 infections

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1996, Digestive Diseases and Sciences.

Genotyping of hepatitis C virus by the polymerase chain reaction: a comparison of two PCR-based methods using core or NS5 primers

K. Chayama, K. Ikeda, H. Kumada, 1995 .

Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology.

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Internal medicine.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Internal medicine.

The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Internal medicine.

The Efficacy of 24-Week Interferon Monotherapy for Type C Liver Cirrhosis in Japanese Patients with Genotype 1b and Low Virus Load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Intervirology.

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Long-Term Outcome after Interferon Therapy in Elderly Patients with Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Efficacy of Interferon Therapy in Elderly Patients with Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Significance of Serum Ribavirin Concentration in Combination Therapy of Interferon and Ribavirin for Chronic Hepatitis C

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Intervirology.

Interferon Therapy for 2 Years or Longer Reduces the Incidence of Hepatocarcinogenesis in Patients with Chronic Hepatitis C Viral Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

Sustained Negativity for HCV-RNA over 24 or More Months by Long-Term Interferon Therapy Correlates with Eradication of HCV in Patients with Hepatitis C Virus Genotype 1b and High Viral Load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Randomized controlled clinical trial of lymphoblastoid interferon-α for chronic hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001 .

Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Journal of Gastroenterology.

Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Usefulness of the Serum KL-6 Assay in Patients with Hepatitis C Virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Serum levels of γ-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003 .

Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of Clinical Microbiology.

Typing six major hepatitis C virus genotypes by polymerase chain reaction using primers derived from nucleotide sequences of the NS5 region

K. Chayama, H. Handa, M. Kobayashi, 1996 .

Biochemical and histological features of hepatitis G virus infection

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Journal of gastroenterology and hepatology.

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.

Yusuke Nakamura, K. Chayama, Y. Karino, 2011, The Journal of infectious diseases.

Utility of Detection of Telaprevir-Resistant Variants for Prediction of Efficacy of Treatment of Hepatitis C Virus Genotype 1 Infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Clinical Microbiology.

Emergence of telaprevir‐resistant variants detected by ultra‐deep sequencing after triple therapy in patients infected with HCV genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of medical virology.

Evolution of simeprevir‐resistant variants over time by ultra‐deep sequencing in HCV genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Journal of medical virology.

Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology.

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Influence of amino‐acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology.

Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all‐oral direct‐acting antiviral regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Journal of Clinical Microbiology.

Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Intervirology.

Amino Acid Substitutions in the Hepatitis C Virus Core Region and Lipid Metabolism Are Associated with Hepatocarcinogenesis in Nonresponders to Interferon plus Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Intervirology.

Long‐term interferon monotherapy reduces the risk of HCV‐associated hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2012, Intervirology.

Efficacy and safety in sitagliptin therapy for diabetes complicated by non‐alcoholic fatty liver disease

Yoshiyuki Suzuki, H. Sone, M. Kobayashi, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Intervirology.

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study

T. Matsui, H. Ogata, T. Hibi, 2020, Intestinal research.

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of Clinical Virology.

Evolution of simeprevir‐resistant variants in virological non‐responders infected with HCV genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Journal of medical virology.

Circulating microRNA‐122 levels are important predictor of hepatitis B virus surface antigen seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region

K. Chayama, H. Handa, Yoshiyuki Suzuki, 1999, Journal of medical virology.

The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real‐life settings

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Hepatology.

Correlation of Histopathological Features andGenetic Variations with Prognosis of JapanesePatients with Nonalcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016 .

Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Oncology.

Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Journal of medical virology.

Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2020, Internal medicine.

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Journal of Gastroenterology.

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Internal medicine.

Serial changes in liver stiffness and controlled attenuation parameter following direct‐acting antiviral therapy against hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Oncology.

hepatocarcinogenesis following eradication of HCV RNA

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015 .

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Internal medicine.

Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay.

K. Tadokoro, Toshikazu Yamaguchi, M. Nagano, 2013, Journal of virological methods.

Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non‐responders infected with HCV genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct‐acting antivirals regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Virological and Biochemical Features in Elderly HCV Patients with Hepatocellular Carcinoma: Amino Acid Substitutions in HCV Core Region as Predictor of Mortality after First Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Common genetic polymorphism of ITPA gene affects ribavirin‐induced anemia and effect of peg‐interferon plus ribavirin therapy

Yusuke Nakamura, M. Imamura, K. Chayama, 2011, Journal of medical virology.

Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology communications.

Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, BMC Gastroenterology.

Detection of TERT promoter mutation in serum cell‐free DNA using wild‐type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Journal of medical virology.

Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Difference in malignancies of chronic liver disease due to non‐alcoholic fatty liver disease or hepatitis C in Japanese elderly patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Performance of autotaxin as a serum marker for liver fibrosis

K. Koike, M. Kurano, J. Aoki, 2018, Annals of clinical biochemistry.

Association of HLA-DR14 with the Treatment Response in Japanese Patients with Autoimmune Hepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Digestive Diseases and Sciences.

Functional Analysis of Hepatitis C Virus Envelope Proteins, Using a Cell-Cell Fusion Assay

Mariko Kobayashi, I. Singh, Ila R Singh, 2006, Journal of Virology.

Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases

F. Kondo, Yoshiyuki Suzuki, K. Kinowaki, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication

M. Imamura, K. Chayama, Y. Karino, 2020, Journal of Gastroenterology.

Fulminant Hepatitis due to de novo Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Internal medicine.

Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long‐term other nucleotide analog treatment in patients with chronic hepatitis B

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection

A. Tsubota, Y. Suzuki, M. Kobayashi, 2004, Journal of viral hepatitis.

Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Hepatology communications.

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Internal medicine.

Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology communications.

Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Internal medicine.

Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, BMC Gastroenterology.

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Gut and liver.

Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2022, Oncology.

Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Hepatology International.

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, H. Kumada, 2013, Journal of medical virology.

Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon α

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Journal of Gastroenterology.

Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

A randomized, double-blind, controlled trial of natural interferon-β therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1996, Journal of Gastroenterology.

A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b.

H. Kumada, N. Akuta, Mariko Kobayashi, 2007, Journal of virological methods.

Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients

A. Lok, Hwai I. Yang, T. Tseng, 2020, Clinical and translational gastroenterology.

Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Prevalence of HCV genotype among patients with chronic liver diseases in the Tokyo metropolitan area

K. Chayama, K. Ikeda, H. Kumada, 1994, Journal of Gastroenterology.

Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Studies on the family of HBs positive antigen whose different subtypes existing in the same family.

K. Chayama, K. Ikeda, H. Kumada, 1989 .

Effect of lymphoblastoid alfa-interferon in patients with chronic hepatitis C having different genotypic subtype of hepatitis C virus

K. Chayama, A. Tsubota, K. Ikeda, 1993, Gastroenterologia Japonica.

Two cases receiving retreatment with 12 weeks of glecaprevir and pibrentasvir for HCV genotype 2 infection who failed prior glecaprevir and pibrentasvir therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Kanzo.

Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Oncology.

H. Kumada, Y. Arase, M. Kobayashi, 2013 .

Reply: To PMID 22991257.

H. Kumada, Y. Arase, M. Kobayashi, 2013, Hepatology.

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study

H. Ogata, T. Hibi, Mariko Kobayashi, 2020, Intestinal research.

Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

Interferon retreatment of nonresponders with HCV-RNA-Positive chronic hepatitis C

K. Chayama, A. Tsubota, K. Ikeda, 1994, Journal of Gastroenterology.

Alanine aminotransferase and HCV-RNA responses following interferon therapy of HCV-RNA positive chronic hepatitis

K. Chayama, A. Tsubota, K. Ikeda, 1992, Gastroenterologia Japonica.

Interferon therapy for chronic hepatitis C.

K. Chayama, K. Ikeda, H. Kumada, 1991 .

The usefulness of HCV antibody titers in interferonn therapy

K. Chayama, K. Ikeda, H. Kumada, 1990 .

Positive rate of C-100 antibody and changes of long term follow up cases of chronic liver disease.

K. Chayama, K. Ikeda, H. Kumada, 1991 .

Genetic polymorphism in cyclooxygenase‐2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C

Takayoshi Ito, H. Kumada, Mariko Kobayashi, 2012, Journal of viral hepatitis.

Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, BMC Gastroenterology.

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology Research.

Effect of early antiviral agent therapy (NS3 and NS5A inhibitors) in chronic hepatitis C null responders

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011 .

Infection Treatment of Hepatitis C Virus Genotype 1 Variants for Prediction of Efficacy of Utility of Detection of Telaprevir-Resistant

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013 .

Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection.

K. Chayama, A. Tsubota, K. Ikeda, 1994, Hepatology.

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity–determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1997, Hepatology.

Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non‐B, non‐C liver cirrhosis: a cohort study

Yoshiyuki Suzuki, Y. Suzuki, K. Ikeda, 2009, Journal of viral hepatitis.

Molecular analysis of intraspousal transmission of hepatitis C virus.

K. Chayama, A. Tsubota, K. Ikeda, 1995, Journal of hepatology.

The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Internal medicine.

Usefulness of hepatitis C virus RNA counts by second generation HCV bDNA-probe in chronic hepatitis C based on the HCV genotype

K. Chayama, A. Tsubota, Y. Suzuki, 1998, Journal of Gastroenterology.

Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, BMC Gastroenterology.

Impact of sodium-glucose co-transporter 2 inhibitor for non-alcoholic fatty liver disease complicated by diabetes mellitus -Prospective study based on the serial liver biopsy-

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016 .

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis

H. Yamanaka, Kazuhiko Yamamoto, N. Miyasaka, 2015, Modern rheumatology.

Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology International.

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Journal of Gastroenterology.

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B

K. Chayama, Y. Karino, N. Hiramatsu, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2023, Hepatology research : the official journal of the Japan Society of Hepatology.

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2023, Oncology.

TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Oncology.

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of hepatology.

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP‐424), pegylated interferon and ribavirin for 12 weeks

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology Research.

Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Intervirology.